New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications

Expert Opinion on Therapeutic Patents

Volumn 7, Issue 8, 1997, Pages 843-858

  Costantino, L ^a   Rastelli, G ^a   Cignarella, G ^a   Vianello, P ^a   Barlocco, D ^a  

^a 1st Chim Farmaceutico/Tossicologico ^*  (Italy)

Author keywords

AGEs; Aldose reductase; Aldose reductase inhibitors; Long term diabetic complications; Polyol pathway; PPAR receptors

Indexed keywords

1 [(3 BROMO 2 BENZO[B]FURANYL)SULFONYL]HYDANTOIN; 3,4 DIHYDRO 2,8 DIISOPROPYL 3 THIOXO 2H 1,4 BENZOXAZINE 4 ACETIC ACID; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; FIDARESTAT; MINALRESTAT; POLYOL; PONALRESTAT; RISARESTAT; SORBINIL; TOLRESTAT; TROGLITAZONE; UNCLASSIFIED DRUG; WP 921; ZOPOLRESTAT;

CATARACT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0030751728     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.7.8.843     Document Type: Review

References (84)